18 results on '"CAMPOS, S."'
Search Results
2. A phase I study AZD2171 and Temsirolimus in advanced GYN cancers
- Author
-
Campos, S., primary, Berlin, S., additional, Lundquist, C., additional, Roche, M., additional, Whalen, C., additional, Horowitz, N., additional, and Penson, R., additional
- Published
- 2012
- Full Text
- View/download PDF
3. STAC: A phase II study of carboplatin/paclitaxel/bevacizumab followed by randomization to either bevacizumab alone or erlotinib and bevacizumab in the upfront management of patients with ovarian, fallopian tube or peritoneal cancer
- Author
-
Campos, S., primary, Atkinson, T., additional, Berlin, S., additional, Roche, M., additional, Whalen, C., additional, Matulonis, U., additional, Horowitz, N., additional, Birrer, M., additional, and Penson, R., additional
- Published
- 2011
- Full Text
- View/download PDF
4. Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: The modified triple doublet regimen
- Author
-
Matulonis, U.A., primary, Campos, S., additional, Krasner, C.N., additional, Duska, L.R., additional, Penson, R.T., additional, Falke, R., additional, Roche, M., additional, Smith, L.M., additional, Lee, H., additional, and Seiden, M.V., additional
- Published
- 2006
- Full Text
- View/download PDF
5. Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies1
- Author
-
PENSON, R, primary, SEIDEN, M, additional, GOODMAN, A, additional, FULLER, A, additional, BERKOWITZ, R, additional, MATULONIS, U, additional, KRASNER, C, additional, LEE, H, additional, ATKINSON, T, additional, and CAMPOS, S, additional
- Published
- 2004
- Full Text
- View/download PDF
6. Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer
- Author
-
Matulonis, U.A., Campos, S., Duska, L., Krasner, C.N., Atkinson, T., Penson, R.T., Seiden, M.V., Verrill, C., Fuller, A.F., and Goodman, A.
- Subjects
- *
CANCER patients , *ANTINEOPLASTIC agents , *CANCER in women , *DRUG therapy - Abstract
Abstract: Objectives. : To evaluate the toxicity and efficacy of cisplatin and gemcitabine in women with recurrent cervical cancer. Methods. : A multi-institutional phase I/II dose finding study of cisplatin and gemcitabine delivered to women with recurrent previously radiated cervical carcinoma. Results. : Twenty eight patients were enrolled. The mean and median age of patients was 51years (age range 35 to 70years). Chemotherapy was given on a 28-day cycle; cisplatin was administered at a fixed dose of 50mg/m2, day 1 and gemcitabine, days 1, 8, and 15. Gemcitabine doses started at 600mg/m2 (dose level 1) and were escalated by 100mg/m2/dose level until 1000mg/m2 (dose level 5). Twenty seven patients were evaluable for toxicity and disease response, and 75 cycles of chemotherapy were administered. Toxicities were predominantly hematological; 18% of patients experienced grade 3 anemia, 37% grade 3 and 11% grade 4 leukopenia, 41% grade 3 neutropenia, and 26% grade 3 thrombocytopenia. The maximally tolerated dose (MTD) was not reached. One patient experienced a dose-limiting toxicity on dose level 2 (febrile neutropenia). One patient had a CR and 3 patients had a PR to therapy (15% response rate), 41% of patients had SD, and 44% had progression of cancer. Median survival was 11.9months. Conclusion. : Although this 28-day gemcitabine and cisplatin regimen in recurrent cervix cancer has tolerable toxicity, 21-day regimens are recommended because of improved practicality, higher dose intensity, and higher response rates. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
7. Feasibility and acceptability of a nurse-led telehealth intervention (BOLSTER) to support patients with peritoneal carcinomatosis and their caregivers: A pilot randomized clinical trial.
- Author
-
Pozzar RA, Enzinger AC, Howard C, Tavormina A, Matulonis UA, Campos S, Liu JF, Horowitz N, Konstantinopoulos PA, Krasner C, Wall JA, Sciacca K, Meyer LA, Lindvall C, and Wright AA
- Subjects
- Humans, Female, Pilot Projects, Middle Aged, Aged, Male, Genital Neoplasms, Female nursing, Genital Neoplasms, Female psychology, Gastrointestinal Neoplasms nursing, Gastrointestinal Neoplasms psychology, Adult, Self Efficacy, Advance Care Planning, Patient Acceptance of Health Care, Telemedicine, Peritoneal Neoplasms secondary, Peritoneal Neoplasms psychology, Peritoneal Neoplasms nursing, Feasibility Studies, Caregivers psychology, Quality of Life
- Abstract
Objective: Patients with advanced gynecologic (GYN) and gastrointestinal (GI) cancers frequently develop peritoneal carcinomatosis (PC), which limits prognosis and diminishes health-related quality of life (HRQoL). Palliative procedures may improve PC symptoms, yet patients and caregivers report feeling unprepared to manage ostomies, catheters, and other complex needs. Our objectives were to (1) assess the feasibility of an efficacy trial of a nurse-led telehealth intervention (BOLSTER) for patients with PC and their caregivers; and (2) assess BOLSTER's acceptability, potential to improve patients' HRQoL and self-efficacy, and potential impact on advance care planning (ACP)., Methods: Pilot feasibility RCT. Recently hospitalized adults with advanced GYN and GI cancers, PC, and a new complex care need and their caregivers were randomized 1:1 to BOLSTER or enhanced discharge planning (EDP). We defined feasibility as a ≥ 50% approach-to-consent ratio and acceptability as ≥70% satisfaction with BOLSTER. We assessed patients' HRQoL and self-efficacy at baseline and six weeks, then compared the proportion experiencing meaningful improvements by arm. ACP documentation was identified using natural language processing., Results: We consented 77% of approached patients. In the BOLSTER arm, 91.0% of patients and 100.0% of caregivers were satisfied. Compared to EDP, more patients receiving BOLSTER experienced improvements in HRQoL (68.4% vs. 40.0%) and self-efficacy for managing symptoms (78.9% vs. 35.0%) and treatment (52.9% vs. 42.9%). The BOLSTER arm had more ACP documentation., Conclusions: BOLSTER is a feasible and acceptable intervention with the potential to improve patients' HRQoL and promote ACP. An efficacy trial comparing BOLSTER to usual care is underway., Trial Registration: ClinicalTrials.gov: NCT03367247; PI: Wright., Competing Interests: Declaration of competing interest The authors have no conflicts of interest to declare., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
8. Experiences of patients with peritoneal carcinomatosis-related complex care needs and their caregivers.
- Author
-
Pozzar RA, Wall JA, Tavormina A, Thompson E, Enzinger AC, Matulonis UA, Campos S, Meyer LA, and Wright AA
- Subjects
- Humans, Caregivers psychology, Palliative Care methods, Peritoneal Neoplasms therapy, Terminal Care methods, Hospice Care
- Abstract
Background: Patients with peritoneal carcinomatosis (PC) frequently undergo palliative procedures, yet these patients and their caregivers report being unprepared to manage ostomies, drains, and other complex care needs at home. The purpose of this study was to characterize the unique needs of these patients and their caregivers during care transitions., Methods: Patients completed measures of health status and advance care planning, caregivers completed measures of preparedness and burden, and all participants completed measures of depression and anxiety. Participants detailed their experiences in individual, semi-structured interviews. We analyzed data using descriptive statistics and conventional content analysis., Results: Sixty-one patients and 39 caregivers completed baseline measures. Twenty-four (39.3%) patients acknowledged their terminal illness and seven (11.5%) had discussed end-of-life care preferences with clinicians. Most (26/39, 66.7%) caregivers provided daily care. Among caregivers who managed symptoms, few were taught how to do so (6/20, 30%). Seven patients (11.5%) and seven caregivers (17.9%) met case criteria for anxiety, while 15 patients (24.6%) and two caregivers (5.1%) met case criteria for depression. Interview participants described a diagnosis of PC as a turning point for which there is no road map and identified the need for health systems change to minimize suffering., Conclusion: Patients with PC and their caregivers are highly burdened by symptoms and care needs. Patients' prognostic understanding and advance care planning are suboptimal. Interventions that train patients with PC and their caregivers to perform clinical care tasks, facilitate serious illness conversations, and provide psychosocial support are needed., Competing Interests: Declaration of Competing Interest The authors have no conflicts of interest to declare., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
9. Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer.
- Author
-
Liu JF, Gray KP, Wright AA, Campos S, Konstantinopoulos PA, Peralta A, MacNeill K, Morrissey S, Whalen C, Dillon D, and Matulonis UA
- Subjects
- Antineoplastic Combined Chemotherapy Protocols adverse effects, Diamines administration & dosage, Diamines adverse effects, Female, Humans, Kaplan-Meier Estimate, MAP Kinase Kinase Kinases antagonists & inhibitors, Middle Aged, Neoplasm Recurrence, Local enzymology, Phosphoinositide-3 Kinase Inhibitors, Progression-Free Survival, Proto-Oncogene Proteins c-akt antagonists & inhibitors, Pyrazoles administration & dosage, Pyrazoles adverse effects, Pyridones administration & dosage, Pyridones adverse effects, Pyrimidinones administration & dosage, Pyrimidinones adverse effects, Signal Transduction drug effects, Uterine Cervical Neoplasms enzymology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Neoplasm Recurrence, Local drug therapy, Uterine Cervical Neoplasms drug therapy
- Abstract
Background: Improved treatment for advanced cervical cancer is needed; currently, treatment options include combined chemotherapy and bevacizumab or pembrolizumab monotherapy for PD-L1 positive disease. PIK3CA and KRAS mutations have been reported in cervical cancers; this study therefore tested dual inhibition of PI3K and RAS signaling by combining the MEK inhibitor trametinib and the AKT inhibitor GSK2141795 in recurrent cervical cancer., Methods: This was an investigator-initiated phase II study combining trametinib and GSK2141795 in patients with recurrent cervical cancer. Primary endpoint was best tumor response; secondary endpoints included progression free survival, overall survival, and safety assessment. Translational objectives included characterization of molecular alterations in PI3K and RAS signaling pathway genes., Results: Planned accrual was 35 patients; 14 patients were enrolled and received at least one dose of study drug before the study was terminated due to discontinuation of GSK2141795 development. There were no confirmed responses; 1 patient had an unconfirmed PR, 8 had stable disease, 3 had progression as best response, and 2 were unevaluable. Toxicities were mostly grade 1 and 2, although 57% of patients experienced grade 3/4 adverse events and 50% patients required a dose reduction., Conclusions: The combination of trametinib and GSK2141795 was feasible but required dose holds and modifications for adverse events; however, anti-cancer activity was minimal, even in patients with PI3K or RAS pathway alterations. Although the study was terminated early after GSK2141795 development was halted, the findings in these 14 patients do not support further development of this combination in cervical cancer., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
10. Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer.
- Author
-
Veneris JT, Lee EK, Goebel EA, Nucci MR, Lindeman N, Horowitz NS, Lee L, Raut CP, Crotzer D, Matulonis U, Konstantinopoulos PA, and Campos S
- Subjects
- Adenocarcinoma diagnosis, Adenocarcinoma secondary, Antibodies, Monoclonal, Humanized administration & dosage, Antineoplastic Combined Chemotherapy Protocols, Carboplatin administration & dosage, Endometrial Neoplasms pathology, Endometrial Neoplasms therapy, Female, Humans, Middle Aged, Mutation, Omentum surgery, Paclitaxel administration & dosage, Pancreatic Neoplasms diagnosis, Pancreatic Neoplasms secondary, Stomach Neoplasms diagnosis, Stomach Neoplasms genetics, Stomach Neoplasms secondary, Adenocarcinoma genetics, Adenocarcinoma therapy, DNA Polymerase II genetics, Endometrial Neoplasms genetics, Pancreatic Neoplasms therapy, Poly-ADP-Ribose Binding Proteins genetics, Stomach Neoplasms therapy
- Abstract
Polymerase-epsilon (POLE)-mutated carcinomas are a rare, but well-known subtype of endometrial cancer. While typically associated with good prognosis, recurrences are documented. Here we present a case of recurrent POLE-mutated endometrial cancer, discuss pathologic features, current methods of molecular classification, and explore therapeutic implications for the POLE-mutation phenotype., (Copyright © 2019. Published by Elsevier Inc.)
- Published
- 2019
- Full Text
- View/download PDF
11. A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial cancer.
- Author
-
Viswanathan AN, Lee H, Berkowitz R, Berlin S, Campos S, Feltmate C, Horowitz N, Muto M, Sadow CA, and Matulonis U
- Subjects
- Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized adverse effects, Bevacizumab, Disease-Free Survival, Endometrial Neoplasms mortality, Endometrial Neoplasms pathology, Feasibility Studies, Female, Humans, Lymphatic Metastasis, Middle Aged, Prospective Studies, Angiogenesis Inhibitors therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Chemoradiotherapy, Endometrial Neoplasms therapy
- Abstract
Objectives: To determine the toxicity and survival rates in a trial of concurrent bevacizumab and external beam radiation (EB) for patients with recurrent endometrial or ovarian cancer., Methods: Nineteen women with recurrent endometrial (n = 15) or ovarian (n = 4) cancer with gross disease involving the vaginal cuff, and/or pelvic nodes and/or para-aortic nodes, cancer were enrolled between 2008 and 2010. All patients received bevacizumab during radiation. Toxicity was assessed at baseline, weekly during treatment and every 3 months for at least 1 year after treatment., Results: All patients completed EB on schedule. For the 15 patients with recurrent endometrial cancer, the 1- and 3-year progression-free survival (PFS was) 80%/67% and overall survival (OS) was 93%/80%. Patients that had a vaginal cuff recurrence alone had a 1- and 3-year PFS of 75%/63% and OS of 100%/75%. Two patients with pelvic node involvement did not recur throughout the entire follow-up period. The 5 patients with para-aortic node involvement had a 1- and 3-year PFS of 80%/60% and OS of 80%/80%. Of the 4 ovarian cancer patients 3 relapsed with 1- and 3-year PFS of 80%/40% and OS of 100%/60%. Toxicities included thrombosis and 1 embolic event in the setting of metastatic disease. No gastrointestinal perforations were noted., Conclusions: Delivering bevacizumab with concurrent radiation provides excellent local tumor control and survival for women with recurrent endometrioid endometrial cancer, particularly those with unresectable nodes. Caution must be used in those at highest risk of developing metastatic disease given the increased risk of thromboembolic events. This regimen may be considered for recurrent gynecologic malignancies in future trials., (© 2013.)
- Published
- 2014
- Full Text
- View/download PDF
12. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.
- Author
-
Esselen KM, Rodriguez N, Growdon W, Krasner C, Horowitz NS, and Campos S
- Subjects
- Antineoplastic Combined Chemotherapy Protocols administration & dosage, Carboplatin administration & dosage, Chemotherapy, Adjuvant methods, Cisplatin administration & dosage, Disease-Free Survival, Fallopian Tube Neoplasms pathology, Female, Humans, Injections, Intraperitoneal, Middle Aged, Neoplasm Staging, Ovarian Neoplasms pathology, Paclitaxel administration & dosage, Peritoneal Neoplasms pathology, Retrospective Studies, Fallopian Tube Neoplasms drug therapy, Fallopian Tube Neoplasms surgery, Neoplasm Recurrence, Local pathology, Ovarian Neoplasms drug therapy, Ovarian Neoplasms surgery, Peritoneal Neoplasms drug therapy, Peritoneal Neoplasms surgery
- Abstract
Objectives: To examine the distribution and outcomes of recurrent disease in patients with ovarian, fallopian tube and peritoneal cancers after optimal cytoreduction and adjuvant intraperitoneal (IP) chemotherapy., Methods: All patients diagnosed with ovarian, fallopian tube, or peritoneal cancer between 2004 and 2009 who underwent optimal cytoreductive surgery and received adjuvant intravenous (IV) and IP chemotherapy with paclitaxel and a platinum-based agent were eligible. Age, performance status, tumor origin, stage, and grade were recorded. First recurrences were identified using CA125 values, radiographic studies, operative notes, and pathology reports. Sites of recurrence were classified as intraperitoneal (IP), extraperitoneal (EP) or distant. Kaplan-Meier estimates and Cox multivariate regression models were used to assess the associations between recurrent disease distribution and progression-free survival (PFS) and overall survival (OS)., Results: One hundred forty-three patients met the criteria for inclusion. The majority were Stage III (86%) and serous histology (77%). Eighty-four (58.7%) received IV/IP paclitaxel/cisplatin per GOG-172 and 59 (41.3%) received IV/IP paclitaxel/carboplatin. Seventy-two percent completed 6 cycles. Ninety (62.9%) patients manifested a recurrence. One-hundred twelve sites of recurrence were identified with 70 (62.5%) IP and 42 (37.5%) EP and distant sites. Nineteen (21%) recurred in more than one site, i.e. both IP and EP locations. Site of recurrence did not impact OS, however, patients who recurred in multiples sites had significantly worse OS (p<0.001)., Conclusion: Approximately 40% of patients treated with IP chemotherapy have a first recurrence outside the peritoneal cavity. Though site of recurrence did not affect OS those with multi-focal recurrence demonstrate worse survival., (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
13. Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer.
- Author
-
Matulonis UA, Pereira L, Liu J, Lee H, Lee J, Whalen C, Campos S, Atkinson T, Hill M, and Berlin S
- Subjects
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Bevacizumab, Cyclophosphamide administration & dosage, Disease-Free Survival, Female, Humans, Middle Aged, Pilot Projects, Prospective Studies, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Neoplasm Recurrence, Local drug therapy, Ovarian Neoplasms drug therapy
- Abstract
Objective: Test the safety and efficacy of sequentially blocking angiogenesis by adding oral cyclophosphamide to bevacizumab following cancer progression on bevacizumab in patients with recurrent ovarian cancer., Methods: Eligibility included ≤ 2 lines of treatment for recurrence and measurable cancer by RECIST 1.0. Patients received bevacizumab (15 mg/kg every 3 weeks IV) and upon RECIST progression, oral cyclophosphamide (50mg orally daily) was added. Objectives included safety, toxicities, 3- and 6-month PFS rates, response rate, PFS, and OS., Results: 20 patients were enrolled. Overall response rate was 10%, and 65% of patients had confirmed stable disease (SD). Thirteen of 20 patients received oral cyclophosphamide added to bevacizumab upon bevacizumab progression. Of these 13 patients, 1 patient subsequently achieved a PR (this patient had SD as best response during bevacizumab) and 3 patients had a confirmed SD. For all patients, median PFS was 8.41 months, 6 month PFS rate was 65%, duration of response (DOR) was 7.3 months, and median OS was 22.72 months. Median DOR for patients receiving both bevacizumab and cyclophosphamide was 8.4 months. Most toxicities were grades 1 and 2 and manageable. Grades 3 and grade 4 toxicities included 1 myocardial infarction, 1 gastrointestinal perforation (GIP), and 12/20 patients (60%) developed grade 3 HTN., Conclusions: Addition of oral cyclophosphamide to bevacizumab at the time of cancer progression on bevacizumab appears to have continued anti-cancer effects in a subgroup of patients and appears to be safe. Randomized trials testing combination versus sequential anti-angiogenic therapy for recurrent ovarian cancer are warranted., (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
14. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer.
- Author
-
Duska LR, Berkowitz R, Matulonis U, Muto M, Goodman A, McIntyre JF, Klein A, Atkinson T, Seiden MV, and Campos S
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols adverse effects, Brachytherapy, Carboplatin administration & dosage, Carboplatin adverse effects, Combined Modality Therapy, Doxorubicin administration & dosage, Doxorubicin adverse effects, Drug Administration Schedule, Endometrial Neoplasms pathology, Endometrial Neoplasms surgery, Female, Filgrastim, Granulocyte Colony-Stimulating Factor administration & dosage, Humans, Middle Aged, Neoplasm Staging, Paclitaxel administration & dosage, Paclitaxel adverse effects, Pilot Projects, Recombinant Proteins, Risk Factors, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Endometrial Neoplasms drug therapy, Endometrial Neoplasms radiotherapy
- Abstract
Objectives: To determine the toxicity, tolerability, and feasibility of delivering combination chemotherapy with subsequent radiation therapy to women with high-risk endometrial cancer and to evaluate the long-term bowel toxicity of this regimen., Methods: The trial was approved by the Dana Farber/Partners Cancer Care (DFPCC) Institutional Review Board (IRB). Patients with stage 3 or stage 4 endometrial cancer or patients with high-risk histology and any stage disease were prospectively entered. Complete surgical staging and a normal gated blood pool scan were required prior to entry. Patients were treated with three cycles of paclitaxel (160 mg/m(2) ), doxorubicin (45 mg/m(2)) and carboplatin (AUC 5) (TAC) all on day 1 of a 21-day schedule as an outpatient with G-CSF support. At the conclusion of chemotherapy, patients received radiation therapy (4500 cGy to the whole pelvis) commencing within 35 days of the last cycle of chemotherapy. Paraaortic radiation and/or vaginal brachytherapy were allowed at the discretion of the treating radiation oncologist., Results: Twenty patients were entered onto the trial from November 2000 through February 2003. Eighteen patients successfully completed the trial, and two patients came off trial during chemotherapy (both later completed planned radiation therapy). Patients were initially stage 1 (n = 3), stage 3 (n = 14), and stage 4 (n = 3). Papillary serous was the dominant histology with 13 patients. Chemotherapy was given on average within 32 days of surgery (range 11-63 days) and radiation was initiated on average within 14 weeks of surgery (range 10-18 weeks). Chemotherapy was well tolerated, with 57 total cycles delivered of a planned 60 cycles. Two patients required dose modification in two cycles (two patients in cycle 3 secondary to hematologic toxicity). No grade 3 or grade 4 neurotoxicity was reported. There were six episodes of grade 3 short-term toxicity with radiation therapy reported in a single patient. Late radiotherapy toxicity included bowel obstruction requiring laparotomy in two patients and grade 3 constipation in one patient. Late radiation toxicity data are still being collected as follow-up continues., Conclusions: The TAC chemotherapy regimen is well tolerated and three cycles were delivered successfully with G-CSF support without evidence of the neurotoxicity or cardiac toxicity reported with the cisplatin containing TAP regimen. Standard radiation was deliverable following TAC therapy without excessive toxicity. Further study of this regimen with subsequent radiation therapy is warranted in patients at risk for systemic and regional recurrence of their malignancy.
- Published
- 2005
- Full Text
- View/download PDF
15. A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer.
- Author
-
Seiden MV, Muggia F, Astrow A, Matulonis U, Campos S, Roche M, Sivret J, Rusk J, and Barrett E
- Subjects
- Adult, Aged, Drug Administration Schedule, Drug Carriers, Drug Resistance, Neoplasm, Female, Humans, Liposomes, Middle Aged, Topotecan pharmacology, Antineoplastic Agents administration & dosage, Camptothecin administration & dosage, Camptothecin analogs & derivatives, Ovarian Neoplasms drug therapy
- Abstract
Objectives: To determine the safety and efficacy of a novel topoisomerase I inhibitor, liposomal lurtotecan, in patients with topotecan resistant ovarian cancer., Methods: The trial was an open-label phase II study for patients stratified by resistance to either single agent topotecan or to a prior topotecan-containing regimen. Liposomal lurtotecan was delivered at a dose of 2.4 mg/m(2) on Days 1 and 8 of a 21-day cycle. Dose escalations and reductions were allowed based on hematologic toxicity. Patients were evaluated every two cycles for response to liposomal lurtotecan., Results: Twenty-two women were accrued, with 16 women resistant to single agent topotecan and 6 women resistant to topotecan given in combination with a second chemotherapy agent. Hematologic toxicity consisted of mild to moderate thrombocytopenia, anemia, and neutropenia with mild to moderate gastrointestinal toxicity and fatigue. There were no responses, although eight patients had stable disease., Conclusions: Liposomal lurtotecan at this schedule demonstrates moderate hematologic toxicity and no evidence of clinical activity in a group of heavily pretreated women previously exposed to the topoisomerase I inhibitor topotecan. The study of this agent in alternative patient populations or with alternative schedules is ongoing.
- Published
- 2004
- Full Text
- View/download PDF
16. Phase II trial of anastrozole in women with asymptomatic müllerian cancer.
- Author
-
del Carmen MG, Fuller AF, Matulonis U, Horick NK, Goodman A, Duska LR, Penson R, Campos S, Roche M, and Seiden MV
- Subjects
- Aged, Aged, 80 and over, Anastrozole, Fallopian Tube Neoplasms metabolism, Female, Humans, Middle Aged, Mixed Tumor, Mullerian metabolism, Nitriles adverse effects, Ovarian Neoplasms metabolism, Receptor, ErbB-2 metabolism, Receptors, Estrogen metabolism, Receptors, Progesterone metabolism, Triazoles adverse effects, Antineoplastic Agents, Hormonal therapeutic use, Fallopian Tube Neoplasms drug therapy, Mixed Tumor, Mullerian drug therapy, Nitriles therapeutic use, Ovarian Neoplasms drug therapy, Peritoneal Neoplasms drug therapy, Triazoles therapeutic use
- Abstract
Objective: To evaluate the efficacy and toxicity of the selective aromatase inhibitor anastrozole (Arimidex), we conducted a phase II trial in 53 women with asymptomatic recurrent/persistent müllerian cancer., Methods: Patients with ovarian, peritoneal, or fallopian tube carcinoma were eligible for enrollment. Eligible patients had an ECOG PS < or = 1 and no clinical indication for immediate systemic chemotherapy. Patients were assigned to measurable (cohort 1) or evaluable disease (cohort 2) cohorts, respectively. Patients were treated with anastrozole 1 mg po daily. Monthly follow-up included interim history, physical exam, and CA-125 with radiologic evaluation every 3 months. Estrogen, progesterone, and Her-2/neu receptor status was also evaluated in archived tumor samples., Results: Fifty-three women with a median age of 63 (range, 46-86) years were enrolled. Twenty-nine women enrolled in cohort 1 and 24 in cohort 2. Included were 43, 7, and 3 women with ovarian, primary peritoneal, and fallopian tube carcinoma, respectively. All 53 patients were evaluable for treatment toxicity and response. The median time to disease progression was 85 days (85 days for cohort 1 and 82 days for cohort 2). A partial response was documented in a single patient with measurable disease. Forty-two percent of patients had stable disease (measured as time to treatment termination) for >90 days, 15% for >180 days, 7% for >270 days, and 4% for >360 days. One patient remained on anastrozole at 15 months. Toxicity was modest (grade I) and infrequent, with the most common toxicities being fatigue and hot flashes. There were no thrombotic complications. Median time to progression for patients with estrogen receptor-positive tumors was 72 days as compared to 125 days for those with tumors negative for the estrogen receptor (P = 0.95, log-rank test). The median time to progression in patients with progesterone-positive tumors was 77 days and 91 days for patients with progesterone-negative tumors., Conclusion: In summary, anastrozole is a well-tolerated oral agent but with minimal tumoricidal activity in women with recurrent/persistent müllerian cancers. A minority of patients demonstrated prolonged stable disease while on this agent.
- Published
- 2003
- Full Text
- View/download PDF
17. A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy.
- Author
-
Seiden MV, Swenerton KD, Matulonis U, Campos S, Rose P, Batist G, Ette E, Garg V, Fuller A, Harding MW, and Charpentier D
- Subjects
- ATP Binding Cassette Transporter, Subfamily B, Member 1 antagonists & inhibitors, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols pharmacokinetics, Female, Humans, Middle Aged, Multidrug Resistance-Associated Proteins antagonists & inhibitors, Neoplasm Recurrence, Local drug therapy, Ovarian Neoplasms metabolism, Ovarian Neoplasms pathology, Paclitaxel administration & dosage, Paclitaxel adverse effects, Paclitaxel pharmacokinetics, Piperidines administration & dosage, Piperidines adverse effects, Piperidines pharmacokinetics, Pyridines administration & dosage, Pyridines adverse effects, Pyridines pharmacokinetics, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Ovarian Neoplasms drug therapy
- Abstract
Purpose: Incel (biricodar, VX-710) restores drug sensitivity to P-glycoprotein (MDR1) and multidrug-resistance-associated protein (MRP1) expressing cells. This phase II study evaluated the safety/tolerability, pharmacokinetics, and efficacy of VX-710 plus paclitaxel in women with advanced ovarian cancer refractory to prior paclitaxel therapy., Experimental Design: Eligible patients had paclitaxel-refractory disease defined as progressive disease after a minimum of two cycles of paclitaxel (weekly or 3-week schedule) or relapsed disease within 4 months of prior paclitaxel therapy. Patients received 80 mg/m(2) paclitaxel over 3 h starting 4 h after initiation of a 24-h continuous intravenous infusion of 120 mg/m(2)/h VX-710. Cycles were repeated every 3 weeks., Results: Fifty patients received treatment and 45 were evaluable for response. VX-710 + paclitaxel therapy was generally well tolerated. Myelosuppression was the principal toxicity, with a median Cycle 1 nadir absolute neutrophil count of 0.27 x 10(9) cells/L and a 47% overall incidence of Grade 4 neutropenia. Mild to moderate peripheral neuritis or neuropathy was the primary nonhematologic toxicity, affecting 62% of patients. Other nonhematologic toxicities were generally mild to moderate and reversible. Paclitaxel area under the concentration-versus-time curve (AUC) (16 +/- 5.3 microg x h/mL) during the first treatment cycle was comparable to standard 175 mg/m(2) paclitaxel administered over 3 h. Of the 3 patients who achieved partial responses, 2 had progressed during prior paclitaxel therapy. Twelve patients maintained stable disease and 14/45 (31%) of patients had CA-125 reductions of 50-90% for up to 24 weeks. The median time-to-disease progression was 10 weeks for the intent-to-treat population and 20.7 weeks for the CA-125 responders., Conclusions: The results suggest that VX-710 with paclitaxel has modest activity in paclitaxel-resistant ovarian cancer. Further research is warranted in less heavily treated patients.
- Published
- 2002
- Full Text
- View/download PDF
18. The clinical utility of liposomal doxorubicin in recurrent ovarian cancer.
- Author
-
Campos SM, Penson RT, Mays AR, Berkowitz RS, Fuller AF, Goodman A, Matulonis UA, Muzikansky A, and Seiden MV
- Subjects
- Adult, Aged, Antibiotics, Antineoplastic adverse effects, Doxorubicin adverse effects, Female, Humans, Liposomes, Middle Aged, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local metabolism, Ovarian Neoplasms metabolism, Receptor, ErbB-2 biosynthesis, Retrospective Studies, Antibiotics, Antineoplastic administration & dosage, Doxorubicin administration & dosage, Ovarian Neoplasms drug therapy
- Abstract
Objectives: The aim of this study was to determine the efficacy and toxicity of single agent off-protocol, liposomal doxorubicin (Doxil Alza), in consecutive patients with recurrent ovarian cancer and to investigate the influence of HER-2/neu expression on response to liposomal doxorubicin., Patients and Methods: Retrospective analysis of 72 consecutive patients treated, typically with liposomal doxorubicin 40 mg/m(2) q28 days between January 1997 and December 1998. Results. Twenty-nine patients (40%) had platinum- and taxane-resistant tumors. Nineteen patients (27%) responded with clinical or radiological evidence of response with reduction in CA-125 of >50%. One complete response (CR) and 7 partial responses (PRs) occurred in platinum- and taxane-resistant patients (radiological response (RR) 29%) and 8 PRs occurred in patients with visceral metastases (RR 28%). Time to progression was 5.3 (2.1-12.1) months. Only 7 dose delays (3%) and 20 dose reductions (8%) were necessary in 265 cycles of treatment. Hematological toxicity was generally mild with grade (Gr) > or =III neutropenia in 1 (2%), Gr > or =III thrombocytopenia in 1 (1%), and Gr > or =III anemia in 8 patients (11%). One patient (1%) was admitted with fever and neutropenia. Other toxicity was minimal with Gr > or =III mucositis occurring in 3 patients (4%). Gr > or =III cutaneous toxicity was seen in 6 patients (8%). Three patients (4%) had a >10% fall in ejection fraction but there was no unequivocal clinical heart failure., Conclusions: The data suggest that liposomal doxorubicin is an active drug in both taxane- and platinum-sensitive and resistant recurrent ovarian cancer. Liposomal doxorubicin is associated with tolerable toxicity and is particularly well tolerated in patients with multiple prior lines of treatment., (Copyright 2001 Academic Press.)
- Published
- 2001
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.